The history of the global pharmaceutical industry has largely been a monologue, spoken by the West and listened to by the East. For the better part of the post-war era, the United States, through the engines of the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), served as the world’s laboratory.
fredag 23. januar 2026
Accelerationist State: China’s biopharma revolution
The continuous stream of drug approvals by Chinese pharmaceutical companies should be a source of awe to any global innovation investor. There are multiple reasons that have led to the current point. However, one key contributor is China’s drug approval policy transformation, which is one of the most under-discussed and massively impactful policy narratives of our era.
The history of the global pharmaceutical industry has largely been a monologue, spoken by the West and listened to by the East. For the better part of the post-war era, the United States, through the engines of the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), served as the world’s laboratory.
The history of the global pharmaceutical industry has largely been a monologue, spoken by the West and listened to by the East. For the better part of the post-war era, the United States, through the engines of the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), served as the world’s laboratory.
